JP2019510807A - バクテリオクロロフィル誘導体を含む、がんの治療のための併用療法 - Google Patents

バクテリオクロロフィル誘導体を含む、がんの治療のための併用療法 Download PDF

Info

Publication number
JP2019510807A
JP2019510807A JP2018553149A JP2018553149A JP2019510807A JP 2019510807 A JP2019510807 A JP 2019510807A JP 2018553149 A JP2018553149 A JP 2018553149A JP 2018553149 A JP2018553149 A JP 2018553149A JP 2019510807 A JP2019510807 A JP 2019510807A
Authority
JP
Japan
Prior art keywords
bchl
mdsc
inhibitor
pdt
vtp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018553149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510807A5 (https=
Inventor
シェルツ，アヴィグドル
サロモン，ヨラム
アジェミー，リイアチ
ハムリ，ラケル
プレイズ，ディナ
キム，クァンヒ
コールマン，ジョナサン
Original Assignee
イエダ リサーチ アンド ディベロップメント カンパニー リミテッド
イエダ リサーチ アンド ディベロップメント カンパニー リミテッド
メモリアル スローン ケタリング キャンサー センター
メモリアル スローン ケタリング キャンサー センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イエダ リサーチ アンド ディベロップメント カンパニー リミテッド, イエダ リサーチ アンド ディベロップメント カンパニー リミテッド, メモリアル スローン ケタリング キャンサー センター, メモリアル スローン ケタリング キャンサー センター filed Critical イエダ リサーチ アンド ディベロップメント カンパニー リミテッド
Publication of JP2019510807A publication Critical patent/JP2019510807A/ja
Publication of JP2019510807A5 publication Critical patent/JP2019510807A5/ja
Priority to JP2021193514A priority Critical patent/JP2022031823A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018553149A 2016-04-10 2017-04-10 バクテリオクロロフィル誘導体を含む、がんの治療のための併用療法 Pending JP2019510807A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021193514A JP2022031823A (ja) 2016-04-10 2021-11-29 バクテリオクロロフィル誘導体を含む、がんの治療のための併用療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662320549P 2016-04-10 2016-04-10
US62/320,549 2016-04-10
PCT/IL2017/050440 WO2017179053A1 (en) 2016-04-10 2017-04-10 Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021193514A Division JP2022031823A (ja) 2016-04-10 2021-11-29 バクテリオクロロフィル誘導体を含む、がんの治療のための併用療法

Publications (2)

Publication Number Publication Date
JP2019510807A true JP2019510807A (ja) 2019-04-18
JP2019510807A5 JP2019510807A5 (https=) 2020-05-14

Family

ID=58794130

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018553149A Pending JP2019510807A (ja) 2016-04-10 2017-04-10 バクテリオクロロフィル誘導体を含む、がんの治療のための併用療法
JP2021193514A Pending JP2022031823A (ja) 2016-04-10 2021-11-29 バクテリオクロロフィル誘導体を含む、がんの治療のための併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021193514A Pending JP2022031823A (ja) 2016-04-10 2021-11-29 バクテリオクロロフィル誘導体を含む、がんの治療のための併用療法

Country Status (14)

Country Link
US (2) US11278555B2 (https=)
EP (1) EP3442582A1 (https=)
JP (2) JP2019510807A (https=)
KR (2) KR20190008206A (https=)
CN (2) CN118304400A (https=)
AU (2) AU2017250732B2 (https=)
BR (1) BR112018070847A2 (https=)
CA (1) CA3020067A1 (https=)
IL (1) IL262191B2 (https=)
MX (2) MX390751B (https=)
RU (2) RU2021110230A (https=)
SG (1) SG11201808849TA (https=)
WO (1) WO2017179053A1 (https=)
ZA (1) ZA201807187B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10107240B2 (en) 2014-04-04 2018-10-23 Dayco Ip Holdings, Llc Check valves and Venturi devices having the same
CN106458190B (zh) 2014-05-30 2019-12-06 戴科知识产权控股有限责任公司 具有喷射器、气动控制阀和可选择的吸气器的真空创建系统
EP3723785A1 (en) * 2017-12-17 2020-10-21 Yeda Research and Development Co. Ltd Cop9 signalosome (csn) complex modulators and uses thereof
WO2022149934A1 (ko) * 2021-01-08 2022-07-14 가톨릭대학교 산학협력단 암세포의 항암 면역치료를 위한 항체-폴리에틸렌글리콜-광감각제 접합체

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515836A (ja) * 2002-11-17 2006-06-08 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 水溶性陰イオン性バクテリオクロロフィル誘導体及びそれらの使用
JP2010502574A (ja) * 2006-08-23 2010-01-28 イエダ リサーチ アンド デベロップメント カンパニー リミテッド Ｒｇｄペプチドとポルフィリン又は（バクテリオ）クロロフィル光合成剤とのコンジュゲート及びその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE347554T1 (de) 1998-12-09 2006-12-15 Yeda Res & Dev Palladiumsubstituierte bakteriochlorophyllderivate und deren verwendung
IL133253A0 (en) * 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
US8673270B2 (en) 2008-10-23 2014-03-18 Steba Biotech S.A. RGD-containing peptidomimetics and uses thereof
WO2012106343A2 (en) * 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
TWI442945B (zh) * 2011-05-18 2014-07-01 Univ Nat Taiwan 雙效微脂體用於治療的方法
WO2014141289A1 (en) * 2013-03-12 2014-09-18 Amrita Vishwa Vidyapeetham University Photo - chemo composition on the basis of microcapsules with a core -shell structure

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515836A (ja) * 2002-11-17 2006-06-08 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 水溶性陰イオン性バクテリオクロロフィル誘導体及びそれらの使用
JP2010502574A (ja) * 2006-08-23 2010-01-28 イエダ リサーチ アンド デベロップメント カンパニー リミテッド Ｒｇｄペプチドとポルフィリン又は（バクテリオ）クロロフィル光合成剤とのコンジュゲート及びその使用

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 56, JPN6022002625, 2007, pages 641 - 648, ISSN: 0004687282 *
CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 61, JPN6022002631, 2012, pages 353 - 362, ISSN: 0004687281 *
CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 62, JPN6022002633, 2013, pages 383 - 391, ISSN: 0004687279 *
CRESCENZI E: "LOW DOSES OF CISPLATIN OR GEMCITABINE PLUS PHOTOFRIN/PHOTODYNAMIC THERAPY: DISJOINTED CELL 以下備考", MOLECULAR CANCER THERAPEUTICS, vol. VOL:5, NR:3,, JPN5019004209, March 2006 (2006-03-01), US, pages 776 - 785, ISSN: 0004447579 *
GANG SUN: "SYNERGISTIC EFFECTS OF PHOTODYNAMIC THERAPY WITH HPPH AND GEMCITABINE IN PANCREATIC 以下備考", LASERS IN SURGERY AND MEDICINE, vol. VOL:44, NR:9,, JPN5019004206, 27 November 2012 (2012-11-27), US, pages 755 - 761, ISSN: 0004687278 *
JOURNAL OF PHARMACOLOGY AND PHARMACOTHERAPEUTICS, vol. 5, no. 3, JPN6022002629, 2014, pages 186 - 192, ISSN: 0004687280 *
QI XIE: "SYNERGETIC ANTICANCER EFFECT OF COMBINED GEMCITABINE AND PHOTODYNAMIC THERAPY 以下備考", WORLD JOURNAL OF GASTROENTEROLOGY, vol. VOL:15, NR:6,, JPN5019004208, 2009, CN, pages 1 - 10, ISSN: 0004447578 *
YOSHIKAZU NONAKA: "SYNERGIC EFFECT OF PHOTODYNAMIC THERAPY USING TALAPORFIN SODIUM WITH CONVENTIONAL 以下備考", JOURNAL OF SURGICAL RESEARCH, vol. VOL:181, NR:2,, JPN5019004207, May 2013 (2013-05-01), US, pages 234 - 241, ISSN: 0004447577 *

Also Published As

Publication number Publication date
CA3020067A1 (en) 2017-10-19
US20220202838A1 (en) 2022-06-30
AU2017250732B2 (en) 2022-11-10
WO2017179053A1 (en) 2017-10-19
MX2018012392A (es) 2019-08-21
IL262191B2 (en) 2025-01-01
RU2747258C2 (ru) 2021-04-29
IL262191B1 (en) 2024-09-01
ZA201807187B (en) 2020-01-29
RU2018139523A (ru) 2020-05-15
US11278555B2 (en) 2022-03-22
US20190125769A1 (en) 2019-05-02
EP3442582A1 (en) 2019-02-20
SG11201808849TA (en) 2018-11-29
MX2022003190A (es) 2022-04-11
CN109862918A (zh) 2019-06-07
KR20190008206A (ko) 2019-01-23
BR112018070847A2 (pt) 2019-02-05
RU2021110230A (ru) 2021-05-26
MX390751B (es) 2025-03-21
JP2022031823A (ja) 2022-02-22
AU2017250732A1 (en) 2018-11-15
IL262191A (en) 2018-11-29
CN118304400A (zh) 2024-07-09
KR20220139445A (ko) 2022-10-14
AU2023200591A1 (en) 2023-03-09
RU2018139523A3 (https=) 2020-07-07

Similar Documents

Publication Publication Date Title
Luo et al. Emerging strategies in cancer therapy combining chemotherapy with immunotherapy
US20220202838A1 (en) Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative
Huang et al. Multifunctional nanodrug performs sonodynamic therapy and inhibits TGF-β to boost immune response against colorectal cancer and liver metastasis
US20150344577A1 (en) Agents for treating tumors, use and method thereof
Wan et al. Peptide hydrogels loaded with irradiated tumor cell secretions enhance cancer immunotherapy
US20220313822A1 (en) Near-infrared (nir) photoimmunotherapy (pit) for the treatment of cancers using anti-cd25 antibody-phthalocyanine dye conjugate and anti-pd1 antibody
AU2006312013B2 (en) Concurrent chemotherapy and immunotherapy
Wang et al. TMTP1-modified polymeric micelles for the inhibition of ovarian cancer metastasis and recurrence through enhanced photothermal-immunotherapy
KR20070065311A (ko) 항암 치료 및 약제학적 조성물의 조합
Everse et al. Priming of the antitumor response promotes efficacy of interleukin-2 therapy
Lobo Immunological Effects of Photodynamic Therapy
Zhang et al. In situ therapeutic vaccines for leukemia by chemo-nanoadjuvant therapy
Li et al. Fluence rate differences in photodynamic therapy efficacy and activation of immune checkpoints of murine colorectal cancer
Huang et al. A versatile nanoplatform for enhancing the therapeutic efficacy against low-immunogenic TNBC by inducing immunogenic cell death and MHC-I upregulation
Akiyoshi et al. A trial of adjuvant combination chemoimmunotherapy for stage III carcinoma of stomach
Hamri Targeting the microenvironment of 4T1 tumors using RGD-conjugated bacteriochlorophylls as a theranostic tool
Wood et al. Autologous Vaccine and Adoptive Cellular Immunotherapy as Treatment for Brain Tumors
KR20200089539A (ko) 종양세포 용해물이 봉입된 암 치료용 ｃｏ₂발생 리포좀
Viehl et al. A tat fusion protein-based tumor vaccine for breast cancer
Greenberg et al. Human colon adenocarcinoma in the SCID/CB6 radiation chimera a new model for xenograph colon cancer--is susceptible to adoptive transfer of allogeneic human peripheral blood mononuclear cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200402

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210601

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211129

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211129

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211222

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220104

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220128

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220201

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230124

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230314

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20230404

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20230404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240129